Scientists can now see a previously hidden dimension of the immune system thanks to BCR-MERFISH, a new imaging technology developed by researchers at Boston Children's Hospital. By mapping where different groups of antibody-producing cells are located in tissue, the technology could help researchers better understand how immune responses contribute to disease and eventually inform new approaches to diagnosis and treatment. The breakthrough, published in Nature Methods, opens new possibilities for investigating inflammatory bowel disease, autoimmune disorders, infections, and cancer.
"This work allows us to see the aspects of spatial organization of the adaptive immune system in tissues that we could never see before," said Jeffrey R. Moffitt, PhD, senior author and Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital.
Building on existing technologies
Plasma cells are immune cells that produce antibodies, the proteins that help the body recognize and fight threats. Two plasma cells may look nearly identical under a microscope yet produce antibodies that recognize very different targets. Previously, imaging technologies could identify cell types and states but could not readily distinguish these important differences among plasma cells.
BCR-MERFISH builds on MERFISH, short for multiplexed error-robust fluorescence in situ hybridization, which uses microscopy to measure RNA and reveal which genes are active in cells. Evan Yang, PhD, a former graduate student in Moffitt's lab and lead author, adapted MERFISH to distinguish groups of plasma cells based on selected antibody receptor gene features while also measuring gene activity in surrounding cells.
"People have started to put this information in space, but BCR-MERFISH increases the resolution we have dramatically," Moffitt said.
Applying BCR-MERFISH in the gut
To demonstrate the technology's capabilities, researchers studied the small intestines of mice. In two extended sections of intestinal tissue, they imaged more than 300,000 cells and identified 434 distinct plasma-cell groups based on antibody receptor gene usage.
The maps revealed that some groups of antibody-producing cells formed unexpected clusters along the intestine rather than being evenly distributed throughout the tissue. "We did not expect to see these clusters at all," Moffitt said. Researchers do not yet know what causes the clusters or what they mean for immune function, he added.
The team also compared mice with typical gut microbes with germ-free mice raised without microorganisms. As expected, germ-free mice had fewer plasma cells and less diversity among the identifiable groups.
The ability to connect immune-cell identity with its precise location could help researchers understand how antibody-producing cells behave at sites of inflammation and disease. For example, in inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, tissue architecture changes and plasma cells gather at affected sites. Until now, scientists have had limited ability to distinguish groups of antibody-producing cells within these tissues and examine how they relate to surrounding cells.
Beyond inflammatory bowel disease, BCR-MERFISH could help researchers investigate immune activity in tumors, B-cell lymphomas, and other conditions involving the adaptive immune system.
Moffitt's laboratory is especially interested in the immune system's role in the intestine. His team is already studying human biopsy samples through clinical collaborations, including samples from patients with inflammatory bowel disease. Although BCR-MERFISH is not a diagnostic test or treatment, translating its findings into advances in patient care will require further research.
"Our goal is to build a better understanding of these diseases so that researchers and clinicians can use that knowledge to make a difference in patients' lives," Moffitt said.
The paper, "In situ profiling of plasma cell clonality with image-based single-cell transcriptomics," can be found here .
NOTES:
The paper "In situ profiling of plasma cell clonality with image-based single-cell transcriptomics," lists Evan Yang, Jose Aceves-Salvador, Carlos Castrillon, Uli S. Herrmann, Elliot H. Akama-Garren, Michael C. Carroll, and Jeffrey R. Moffitt as authors. The researchers are affiliated with Boston Children's Hospital, Harvard Medical School, and the Broad Institute of Harvard and MIT.